Observational studyEuropean heart journal. Acute cardiovascular care2026
Safety and efficacy of ivabradine in the treatment of patients with acute myocardial infarction: a real-world propensity score matching study.
Observational study in European heart journal. Acute cardiovascular care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsIvabradine, a selective If channel inhibitor, reduces heart rate without impairing myocardial contractility. Evidence regarding its safety and efficacy in the acute phase of acute myocardial infarction (AMI) remains limited and conflicting. METHODS AND
resultsWe analysed data from 136 033 patients with AMI admitted to 82 hospitals in Tianjin, China, between 2010 and 2024. Primary outcomes were in-hospital mortality and 1-year cardiac mortality; secondary outcomes included 1-year all-cause mortality and other adverse events. Propensity score matching (PSM) was used to balance baseline characteristics between patients receiving ivabradine during hospitalization and controls. Logistic regression and Cox proportional hazards models were used to estimate outcome associations. Pre-specified subgroup analyses were conducted. Robustness was assessed using inverse probability of treatment weighting, overlap weighting, E-value analysis, complete-case analysis, treatment-pattern comparator analysis according to background beta-blocker use, and beta-blocker dose-intensity analysis. After PSM, in-hospital ivabradine use was associated with higher in-hospital mortality [aOR, 1.66 (95% CI, 1.19-2.32); P = 0.003], 1-year cardiac mortality [aHR, 1.22 (95% CI, 1.01-1.47); P = 0.043], and 1-year all-cause mortality [aHR, 1.19 (95% CI, 1.01-1.40); P = 0.040] in the fully adjusted model. No significant differences were observed in other secondary outcomes. Subgroup analyses suggested stronger associations among patients aged ≥65 years. Additional analyses showed that the mortality association was most pronounced among patients receiving ivabradine without concomitant beta-blocker. Sensitivity analyses yielded directionally consistent findings.
conclusionIn this large real-world AMI cohort, in-hospital ivabradine use was associated with higher in-hospital and 1-year mortality, without clear evidence of benefit for other secondary outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.